Drug Trial Radar · NCT05222633
Anti-VEGF in Real-world
Last checked: Nov 20, 2026Latest source record: Feb 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,000
Planned (sponsor's estimate)
Start
Jan 1, 2022
Primary completion
Jan 1, 2023
Study completion May 1, 2023
Sponsor
- Lead sponsor
- Wenbin WeiAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 3, 2022
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 35 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Anti-vascular endothelial growth factor therapy is the major intervention for treating ischemic retina diseases. According to FDA and China Food and Drug Administration, Ranibizumab, Aflibercept, and Conbercept are major types of anti-vascular endothelial growth factor therapy drugs. In the current study, the primary aim is to observe the visual acuity, anatomy effect of anti-vascular endothelial growth factor therapy in the real-world setting.
Conditions
- Neovascular Age-related Macular Edema
- Diabetic Macular Edema
- Choroidal Neovascular Membrane
- Non-proliferative Diabetic Retinopathy
- Retinal Vein Occlusion
- Proliferative Diabetic Retinopathy
Interventions
RanibizumabDrug
Ranibizumab 0.5mg/0.05ml intravitreal injection
AfliberceptDrug
Aflibercept 2.0mg/0.05ml intravitreal injection
ConberceptDrug
Conbercept 0.5mg/0.05ml intravitreal injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Visual acuityTime frame: 1 year
- Central subfield thicknessTime frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Wen-Bin Wei
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.